2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T6892,

Summary Table

Category	Details
Risk Factors	Female sex (though malignancy risk is higher in males), age <14 or >70, history of head/neck radiation exposure, family history of thyroid cancer or MEN2/familial medullary thyroid cancer, iodine deficiency
Etiology	Most nodules are benign colloid nodules or adenomas. Malignant etiologies include papillary, follicular, medullary, and anaplastic thyroid carcinoma. Hashimoto thyroiditis can mimic nodules on palpation
Patient Presentation	Incidentally found neck mass or detected on imaging done for other reasons. Most patients are asymptomatic and euthyroid. Compressive symptoms (dysphagia, hoarseness, dyspnea) raise concern for malignancy or large goiter
Classic Physical Exam	Firm, fixed, nontender solitary nodule. Cervical lymphadenopathy. Vocal cord paralysis (hoarseness) strongly suggests malignancy. A soft, mobile nodule is more reassuring
Key Diagnostic Results	TSH is the first lab. If TSH is low, radionuclide (I-123) scan is next. Ultrasound characterizes the nodule (composition, echogenicity, margins, calcifications). Fine needle aspiration (FNA) biopsy is the confirmatory test, interpreted via the Bethesda system
Management	Observation with serial ultrasound for benign cytology. Lobectomy or total thyroidectomy for malignant or suspicious cytology. Molecular testing for indeterminate cytology (Bethesda III/IV). Radioactive iodine ablation post-thyroidectomy for select differentiated thyroid cancers
Keywords	"Cold nodule," "psammoma bodies," "Orphan Annie eyes," "Hurthle cells," "calcitonin elevation," "incidental thyroid nodule," "Bethesda classification," "ATA risk stratification"

1. Pathophysiology

Thyroid nodules represent focal areas of abnormal thyroid cell growth within an otherwise normal gland. The majority arise from clonal expansion of follicular epithelial cells, producing benign adenomas or colloid nodules. The fundamental question on any exam vignette is not "what is this nodule" but rather "is this nodule malignant, and how do I determine that systematically?"

The thyroid gland concentrates iodine and synthesizes T3/T4 under TSH stimulation. When a nodule is autonomously functioning, it produces thyroid hormone independent of TSH, which suppresses TSH through negative feedback. This is the rationale behind checking TSH first: a suppressed TSH suggests the nodule is "hot" (functioning), and hot nodules are almost never malignant. The next step in that scenario is a radionuclide scan (I-123 scintigraphy) to confirm autonomous function. If the nodule is hot, FNA is not needed.

Conversely, a normal or elevated TSH means the nodule is not autonomously functioning, and malignancy must be excluded. This is where ultrasound characterization and FNA biopsy become central. The pathophysiology of thyroid malignancy varies by type: papillary carcinoma (the most common, ~80%) spreads via lymphatics and is associated with radiation exposure and RET/PTC rearrangements. Follicular carcinoma invades through the capsule and spreads hematogenously to bone and lung. Medullary carcinoma arises from parafollicular C cells (not follicular epithelium), secretes calcitonin, and is associated with MEN2A/2B and RET proto-oncogene mutations. Anaplastic carcinoma is a rapidly growing undifferentiated tumor in elderly patients with an extremely poor prognosis.

The reason compressive symptoms like hoarseness are alarming is that the recurrent laryngeal nerve runs immediately posterior to the thyroid. A nodule causing vocal cord paralysis implies local invasion, which is a hallmark of aggressive malignancy rather than benign growth.

2. Classification and Clinical Manifestation

Ultrasound Pattern Classification (ATA Risk Stratification)

The ATA guidelines classify nodules by their sonographic appearance to determine which nodules require FNA and at what size threshold.

category	Ultrasound Features	Malignancy Risk	FNA Size Threshold
High suspicion	Solid hypoechoic nodule with one or more: microcalcifications, irregular margins, taller-than-wide shape, extrathyroidal extension, rim calcification with soft tissue component	>70-90%	≥1 cm
Intermediate suspicion	Hypoechoic solid nodule with smooth margins, without the high-suspicion features listed above	10-20%	≥1 cm
Low suspicion	Isoechoic or hyperechoic solid nodule, or partially cystic nodule with eccentric solid component, without the high-suspicion features	5-10%	≥1.5 cm
Very low suspicion	Spongiform or partially cystic nodule without any of the suspicious features described above	<3%	≥2 cm
Benign	Purely cystic nodule (no solid component)	<1%	No FNA recommended

Bethesda System for Reporting Thyroid Cytopathology

Category	Diagnosis	Malignancy Risk	Management
I	Nondiagnostic / Unsatisfactory	5-10%	Repeat FNA with ultrasound guidance
II	Benign	0-3%	Surveillance with serial ultrasound
III	Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS)	10-30%	Repeat FNA, molecular testing, or diagnostic lobectomy
IV	Follicular Neoplasm / Suspicious for Follicular Neoplasm	25-40%	Molecular testing or diagnostic lobectomy
V	Suspicious for Malignancy	50-75%	Lobectomy or total thyroidectomy
VI	Malignant	97-99%	Total thyroidectomy (or lobectomy for small, low-risk papillary carcinoma)

Clinical Features Suggesting Malignancy

Feature	Significance
Rapid nodule growth	Suggests anaplastic carcinoma or lymphoma
Fixed, hard, nontender nodule	Indicates possible local invasion
Cervical lymphadenopathy	Lymphatic spread, classic for papillary carcinoma
Hoarseness / vocal cord paralysis	Recurrent laryngeal nerve invasion
History of head/neck irradiation	Strong risk factor for papillary carcinoma
Family history of MEN2	Screen for medullary thyroid carcinoma with serum calcitonin
Age extremes (<14 or >70)	Higher probability that a nodule is malignant

3. Diagnostic Workup

Test	Role	When to Order
Serum TSH	Best initial test for all thyroid nodules	Every patient with a newly discovered nodule
Radionuclide scan (I-123)	Determines if the nodule is autonomously functioning ("hot")	Only when TSH is subnormal (suppressed)
Thyroid ultrasound	Characterizes sonographic pattern, guides FNA decision	Every patient with a palpable or incidentally found nodule
Fine needle aspiration (FNA)	Most accurate test to assess for malignancy	Based on ATA sonographic pattern and size thresholds
Molecular testing (e.g., Afirma, ThyroSeq)	Refines risk for indeterminate cytology	Bethesda III or IV results
Serum calcitonin	Screens for medullary thyroid carcinoma	If family history of MEN2 or if FNA suggests medullary carcinoma
Serum thyroglobulin	Not useful for initial diagnosis; used as tumor marker post-thyroidectomy	After surgical treatment of differentiated thyroid cancer

The ATA algorithm begins with TSH. This is the single most important first step, and it is the most commonly tested decision point. If TSH is low (subnormal), the algorithm directs you to a radionuclide thyroid scan before FNA. A hot nodule on scintigraphy is almost certainly benign (toxic adenoma) and does not require biopsy. The management shifts to treating hyperthyroidism. If the nodule is "cold" (non-functioning) or "warm" (indeterminate) on the scan, proceed to ultrasound-guided FNA.

If TSH is normal or elevated, skip the radionuclide scan entirely and go directly to thyroid ultrasound. The ultrasound serves two purposes: it risk-stratifies the nodule using the ATA sonographic patterns described above, and it determines whether the nodule meets the size threshold for FNA. A common exam trap is ordering FNA on every nodule regardless of size or ultrasound pattern. The ATA guidelines are clear that purely cystic nodules do not need FNA, and very low suspicion nodules are not biopsied unless they exceed 2 cm.

FNA cytology is interpreted through the Bethesda system. Bethesda II (benign) is followed with serial ultrasound. Bethesda VI (malignant) goes to surgery. The diagnostically challenging categories are Bethesda III and IV (indeterminate cytology), where molecular testing plays an increasingly tested role. Molecular tests like Afirma Gene Expression Classifier act as a "rule-out" test (high negative predictive value), helping to avoid unnecessary surgery for benign nodules with indeterminate cytology.

One critical nuance: follicular carcinoma cannot be diagnosed on FNA alone. FNA shows follicular cells but cannot assess capsular or vascular invasion, which is the defining feature of follicular carcinoma versus follicular adenoma. This is why Bethesda IV requires diagnostic lobectomy for definitive histopathologic evaluation. This distinction between cytology and histology is a heavily tested concept.

4. Management and Treatment

Clinical Scenario	Management	Key Details
Hot nodule (low TSH + functioning on scan)	Treat hyperthyroidism	Radioactive iodine (I-131) ablation, surgery, or antithyroid drugs (methimazole)
Bethesda II (Benign)	Surveillance	Repeat ultrasound at 12-24 months, then at increasing intervals if stable
Bethesda III (AUS/FLUS)	Repeat FNA, molecular testing, or diagnostic lobectomy	Molecular testing increasingly preferred to avoid unnecessary surgery
Bethesda IV (Follicular neoplasm)	Diagnostic lobectomy or molecular testing	Lobectomy needed because FNA cannot distinguish follicular adenoma from carcinoma
Bethesda V (Suspicious)	Lobectomy or total thyroidectomy	Extent of surgery depends on nodule size and risk factors
Bethesda VI (Malignant)	Total thyroidectomy or lobectomy	Lobectomy acceptable for unifocal papillary microcarcinoma (<1 cm) without extrathyroidal extension or nodal metastases. Total thyroidectomy for tumors >4 cm, bilateral disease, extrathyroidal extension, or nodal/distant metastases
Post-thyroidectomy (differentiated cancer)	Radioactive iodine (I-131) ablation + levothyroxine suppression therapy	I-131 ablation for intermediate and high-risk patients. Levothyroxine dose targets TSH suppression to 0.1-0.5 mU/L for intermediate risk, <0.1 mU/L for high risk
Medullary thyroid carcinoma	Total thyroidectomy + central neck dissection	No role for radioactive iodine (C cells do not take up iodine). Screen family members for RET mutations. Monitor with serial serum calcitonin and CEA
Anaplastic thyroid carcinoma	Palliative combined chemoradiation	Surgery rarely curative. Consider tracheostomy for airway compromise. Median survival approximately 5 months

Acute management in thyroid nodules is rarely about emergencies. The exception is anaplastic carcinoma presenting with rapid airway compromise, which may require urgent tracheostomy or debulking.

For differentiated thyroid cancers (papillary and follicular), post-surgical management centers on two pillars. First, radioactive iodine (I-131) remnant ablation destroys residual thyroid tissue and micrometastases. This is not given to every patient; ATA guidelines reserve it for intermediate- and high-risk patients (tumor >4 cm, gross extrathyroidal extension, distant metastases). Low-risk patients (intrathyroidal papillary carcinoma <4 cm without aggressive histology or nodal disease) can be observed without I-131.

Second, levothyroxine (T4) suppression therapy is started post-thyroidectomy at a dose that lowers TSH below the normal range. The rationale is that TSH stimulates thyroid follicular cells, so suppressing TSH reduces the growth stimulus on any residual cancer cells. The degree of suppression is calibrated to risk: high-risk patients target TSH <0.1 mU/L, while low-risk patients with excellent response to treatment can eventually allow TSH to normalize (0.5-2.0 mU/L).

Serum thyroglobulin serves as the tumor marker during long-term surveillance of differentiated thyroid cancer. A rising thyroglobulin after thyroidectomy and I-131 ablation suggests recurrent or persistent disease. Notably, anti-thyroglobulin antibodies can interfere with the assay, producing falsely low values.

For medullary thyroid carcinoma, the key management distinction is that I-131 is useless because C cells lack the sodium-iodide symporter and do not concentrate iodine. Total thyroidectomy with central compartment lymph node dissection is the standard surgical approach. RET mutation testing should be performed in all patients, and if positive, first-degree relatives must be screened.

During pregnancy, thyroid nodule evaluation can proceed with ultrasound and FNA (both safe). Radionuclide scanning is absolutely contraindicated. If FNA reveals malignancy, surgery can be performed in the second trimester if needed, or deferred to postpartum for low-risk differentiated cancers.

5. Differential Diagnosis and Distractors

Differential Diagnosis	Why It Is Similar	Key Discriminator
Thyroglossal duct cyst	Midline neck mass, can be confused with thyroid nodule	Elevates with tongue protrusion and swallowing. Located midline, often between the hyoid bone and thyroid cartilage. Not within the thyroid parenchyma on ultrasound
Multinodular goiter	Multiple thyroid nodules, may present as an enlarged thyroid	Each nodule is evaluated independently by ATA ultrasound criteria. A dominant or suspicious-appearing nodule within a multinodular goiter still requires FNA
Hashimoto thyroiditis	Can present with a firm, irregular thyroid that mimics a nodule on palpation	Elevated anti-TPO antibodies, elevated TSH. Ultrasound shows diffuse heterogeneity rather than a discrete nodule. A true nodule within Hashimoto thyroiditis still requires standard workup
Thyroid lymphoma	Rapidly enlarging thyroid mass, especially in elderly women with Hashimoto thyroiditis	FNA or core biopsy shows lymphoid cells. Flow cytometry confirms lymphoma. Typically presents with compressive symptoms (dysphagia, stridor)
Parathyroid adenoma	Posterior neck mass near the thyroid, may be mistaken for thyroid nodule on imaging	Elevated PTH and calcium. Sestamibi scan localizes parathyroid pathology. Thyroid ultrasound shows the mass is posterior to and separate from the thyroid
Branchial cleft cyst	Lateral neck mass in a young patient	Located along the anterior border of the sternocleidomastoid, not within the thyroid gland. Cystic on ultrasound. History of recurrent infections
Toxic adenoma	Thyroid nodule with hyperthyroid symptoms	Low TSH with hot nodule on radionuclide scan. This is a benign functional nodule, not a malignancy concern. FNA is not indicated

6. Traps and High-Yield Pearls

The single most common mistake students make with thyroid nodule questions is skipping TSH and going directly to FNA or ultrasound. The ATA algorithm is unambiguous: TSH is always the first test. A low TSH fundamentally changes the diagnostic pathway because it triggers a radionuclide scan rather than a biopsy. If a vignette describes a patient with a thyroid nodule and includes symptoms of hyperthyroidism (weight loss, tremor, palpitations, heat intolerance), the answer is almost never "FNA" as the next step.

Another frequently tested trap involves nodule size versus ultrasound pattern. Students reflexively want to biopsy every nodule larger than 1 cm. The ATA guidelines make it clear that the decision to perform FNA depends on both sonographic pattern and size. A 1.3 cm spongiform nodule (very low suspicion) does not meet the 2 cm threshold for FNA and should be observed. Conversely, a 1.0 cm solid hypoechoic nodule with microcalcifications (high suspicion) absolutely requires biopsy.

A third trap is the question stem that presents Bethesda III or IV cytology and asks for the next step. The wrong answer is to repeat the same FNA indefinitely or to jump straight to total thyroidectomy. The tested concept is that molecular testing or diagnostic lobectomy is the appropriate next step for indeterminate cytology. Total thyroidectomy is reserved for confirmed malignancy or high clinical suspicion.

Remember that follicular carcinoma cannot be diagnosed by FNA. Any vignette describing a "follicular lesion" on cytology followed by a question about diagnosis is testing whether you know that only histology (via lobectomy) can distinguish follicular adenoma from carcinoma by demonstrating capsular or vascular invasion.

Finally, for medullary thyroid carcinoma, the pearl is that calcitonin is the tumor marker, not thyroglobulin, and radioactive iodine has no role. If a vignette mentions a thyroid nodule with elevated calcitonin or a family history of pheochromocytoma and hyperparathyroidism (MEN2A), the test-writer is asking you to recognize medullary carcinoma and order RET mutation analysis, not to follow the standard follicular cell algorithm.

1e:["$","$L2d",null,{"article":{"id":"03e171ba-d2fa-4504-acde-9d012b3903df","title":"Nodul Tiroid","content":"$2e","category":"Endokrin-Metabolik","created_at":"2026-05-17T03:27:00.985155+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]